Evidence map›Paper›PMID 41062854›Full record

ArticleAnnals of hematology2025

"B" symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation.

Karolina Chromik, Agata Wieczorkiewicz-Kabut, Patrycja Zielińska, Anna Koclęga, Sabina Kadłubek, Jakub Kamiński, Grzegorz Helbig

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karolina ChromikDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, 40-032, Katowice, Poland. kchromik@sum.edu.pl.ORCID http://orcid.org/0000-0001-6463-7543
Agata Wieczorkiewicz-KabutDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, 40-032, Katowice, Poland.
Patrycja ZielińskaDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, 40-032, Katowice, Poland.
Anna KoclęgaDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, 40-032, Katowice, Poland.
Sabina KadłubekDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, 40-032, Katowice, Poland.
Jakub KamińskiDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, 40-032, Katowice, Poland.
Grzegorz HelbigDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski Street 25, 40-032, Katowice, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with limited curative options. Autologous stem cell transplantation (ASCT) is widely used as consolidation in younger, fit patients. This study aimed to evaluate long-term outcomes after ASCT and identify clinical factors influencing survival.

methodsThis retrospective study included 119 patients with MCL who underwent ASCT between 2007 and 2024 in first complete or partial remission. Patient characteristics, outcomes, and transplant-related complications were assessed.

resultsAt 3 and 5 years, overall survival (OS) rates were 78.3% and 75.2%; progression-free survival (PFS) rates were 76.6% and 73.4%. Median OS and PFS were not reached. The presence of B symptoms at diagnosis and use of CBV (cyclophosphamide, carmustine, and etoposide) conditioning were independently associated with inferior OS and PFS. In contrast, BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning was associated with improved outcomes. Treatment-related mortality at day 100 was 3.4%. Post-transplant complications occurred in 64% of patients, most commonly infections and mucositis. Rituximab maintenance was used in only 17% of cases. The median time to relapse was 13 months, and relapse remained the leading cause of treatment failure.

conclusionsASCT remains a safe and effective consolidation approach in MCL, offering favorable long-term survival. However, the presence of B symptoms and use of CBV conditioning are associated with worse outcomes. These findings underscore the need for risk-adapted treatment strategies and the broader implementation of post-transplant maintenance to enhance disease control.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationLymphoma, Mantle-CellTransplantation ConditioningAdultAgedCarmustineCyclophosphamideCytarabineEtoposideFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateCarmustineCyclophosphamideCytarabineEtoposideAutologous stem cell transplantationBeEAMB symptomsCBV conditioningMantle cell lymphomaPrognostic factorsSurvival

Identifiers

PMID41062854
PMCPMC12552265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.